Matinas BioPharma Holdings, Inc.

Snapshot

Matinas is a distressed micro-cap with zero revenue and an exhausted cash runway after burning $7.0M in FY 2025 against a $4.0M cash balance. The company recently agreed to sell its primary drug assets and merge with GH Power, a move that would leave current shareholders with only about 9% of the combined clean energy entity.

What's Happening Right Now

• Mon 13th Jul '26 · Merger: Matinas agreed to merge with GH Power, where current shareholders would own about 9% of the new clean energy company, and sold its main drug assets to Azurity Pharmaceuticals for up to $21.5 million.
• Fri 26th Jun '26 · Regulatory: The NYSE American notified the company it is not in compliance with listing standards because its stockholders' equity is too low, though the exchange granted a cure period through October 2027.